Literature DB >> 10651936

Carcinogen-modified dendritic cells induce immunosuppression by incomplete T-cell activation resulting from impaired antigen uptake and reduced CD86 expression.

G M Woods1, K V Doherty, R C Malley, M J Rist, H K Muller.   

Abstract

Exposure of the skin to environmental stimuli, such as chemical or physical carcinogens, modifies the local skin environment, including depletion of epidermal Langerhans' cells (LC). Any subsequent exposure of the LC-depleted skin to antigen results in the generation of antigen-specific tolerance. In this study we evaluated the antigen-bearing cells in the draining lymph nodes by capitalizing on the fluorescent nature of the contact sensitizer, fluorescein isothiocyanate (FITC). When FITC was applied to the skin of normal mice, two distinct populations of antigen-bearing cells were identified in the draining lymph nodes. They were classified as either FITChi or FITClo on the basis of their fluorescence intensity and thus the amount of antigen they internalized. Only FITClo cells were detected in the lymph nodes draining FITC-treated murine skin that had been depleted of epidermal LC by prior treatment with the complete carcinogen 9,10-dimethyl 1,2-benzanthracene (DMBA). Functional analysis of these cells revealed that the FITChi cells, but not the FITClo cells, induced antigen-specific T-cell proliferation. Further analysis of the FITClo cells from the DMBA-treated mice demonstrated that these cells had reduced levels of CD80 expression, had substantially reduced levels of CD86 expression and performed poorly as co-stimulator cells in an anti-CD3-mediated proliferative assay. Nonetheless these cells still induced early signs of T-cell activation and interleukin-12 production. Consequently the FITClo cells migrating from the LC-depleted skin, through a combination of reduced antigen presentation and reduced co-stimulatory activity, induced a state of unresponsiveness or anergy in the responder T cells in a similar manner to that observed when antigen presentation occurs in the absence of co-stimulation. We propose that these unresponsive, or anergic cells, account for the antigen-specific tolerance observed in these experiments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10651936      PMCID: PMC2327124          DOI: 10.1046/j.1365-2567.2000.00928.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation.

Authors:  D R DeSilva; K B Urdahl; M K Jenkins
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

2.  Effects of ultraviolet B radiation on human Langerhans cells: functional alteration of CD86 upregulation and induction of apoptotic cell death.

Authors:  F M Rattis; M Concha; C Dalbiez-Gauthier; P Courtellemont; D Schmitt; J Péguet-Navarro
Journal:  J Invest Dermatol       Date:  1998-09       Impact factor: 8.551

3.  In vitro evidence that Langerhans cells can adopt two functionally distinct forms capable of antigen presentation to T lymphocytes.

Authors:  J W Streilein; S F Grammer
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

Review 4.  Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.

Authors:  G Trinchieri
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

5.  Evidence that cutaneous antigen-presenting cells migrate to regional lymph nodes during contact sensitization.

Authors:  M L Kripke; C G Munn; A Jeevan; J M Tang; C Bucana
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

6.  Chemical carcinogens and antigens induce immune suppression via Langerhans' cell depletion.

Authors:  G M Woods; M Qu; S J Ragg; H K Muller
Journal:  Immunology       Date:  1996-05       Impact factor: 7.397

7.  Sensitization through carcinogen-induced Langerhans cell-deficient skin activates specific long-lived suppressor cells for both cellular and humoral immunity.

Authors:  G M Halliday; H K Muller
Journal:  Cell Immunol       Date:  1987-10-01       Impact factor: 4.868

8.  Antigen presented in the local lymph node by cells from dimethylbenzanthracene-treated murine epidermis activates suppressor cells.

Authors:  G M Halliday; L L Cavanagh; H K Muller
Journal:  Cell Immunol       Date:  1988-12       Impact factor: 4.868

9.  Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies.

Authors:  S E Macatonia; S C Knight; A J Edwards; S Griffiths; P Fryer
Journal:  J Exp Med       Date:  1987-12-01       Impact factor: 14.307

10.  Selective activation of the calcium signaling pathway by altered peptide ligands.

Authors:  J Sloan-Lancaster; T H Steinberg; P M Allen
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

View more
  5 in total

1.  Acquisition of immune function during the development of the Langerhans cell network in neonatal mice.

Authors:  A L Dewar; K V Doherty; G M Woods; A B Lyons; H K Muller
Journal:  Immunology       Date:  2001-05       Impact factor: 7.397

2.  Study on immune function of dendritic cells in patients with esophageal carcinoma.

Authors:  Shen-Ren Chen; Yi-Ping Luo; Jin-Kun Zhang; Wei Yang; Zhi-Chao Zhen; Lin-Xin Chen; Wei Zhang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

3.  Impaired CD40-signalling in Langerhans' cells from murine neonatal draining lymph nodes: implications for neonatally induced cutaneous tolerance.

Authors:  C C Simpson; G M Woods; H K Muller
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

Review 4.  Gene-modified dendritic cells for immunotherapy against cancer.

Authors:  Andreas Lundqvist; Pavel Pisa
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 5.  Hazardous air pollutants and asthma.

Authors:  George D Leikauf
Journal:  Environ Health Perspect       Date:  2002-08       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.